Study on the Bioavailability of SHR0302 Tablets With 3 Different Formulations in Healthy Subjects (Single Center, Random, Open, 3 Cycles, 6 Sequences)
Latest Information Update: 22 Oct 2021
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Alopecia areata; Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 19 Oct 2021 Status changed from not yet recruiting to completed.
- 20 Jan 2021 New trial record